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Abstract
Outcome research is a new interesting field in medical research. Some years ago, a document of
the American Society of Clinical Oncology distinguished the outcomes of a treatment into patient-
outcomes (overall survival and quality of life) and cancer-outcomes (response rate), giving higher
priority to patient outcomes. This document is one of the best structured instruments to evaluate
and classify the outcomes in clinical oncology. Nevertheless, although overall survival and quality of
life represent the main patient outcomes in clinical oncology, in the last years many researchers
tried to overcome these recommendations, creating new surrogate end points to assess overall
survival and quality of life. Surrogate end points can be useful tools when they are used to achieve
preliminary data that anticipate the evaluation of the final outcome, but the use of surrogate end
points instead of the main outcomes is quite dangerous, as it can provide wrong answers to clinical
questions. The use (or abuse) of surrogate end points of quality of life has recently favoured some
questionable decisions of the main regulator organs, such as the approval by the Food and Drugs
Administration of the use of gemcitabine in advanced chemotherapy-naive pancreatic cancer, or
mitoxantrone in the palliative treatment of hormone-resistant pancreatic cancer, based on the
improvement in clinical benefit (a non-validated instrument to evaluate the outcome of palliative
chemotherapy) besides a minimal and questionable overall survival, or pain control (evaluated with
a non-validated instrument). A correct use of surrogate end points of quality of life within and not
instead of quality of life assessment should be the engagement of our further efforts in quality of life
research.
Introduction
In the last years, many authors highlighted the impor-
tance of outcome research in oncology, either in clinical
research or in daily clinical practice [1,2]. Outcome
research has been defined as a discipline investigating the
relationship between the results of clinical research and
clinical practice, but a consensus about the real meaning
of outcome is not yet fully reached, and many aspects are
not well defined. In 1996, the American Society of Clini-
cal Oncology (ASCO) published a special article to clarify
the outcomes of a clinical approach to neoplastic disease
[3]. Based on the distinction between activity and effective-
ness of a treatment, the outcomes were divided into cancer-
outcomes (response rate) and patient-outcomes (mainly sur-
vival and quality of life). Moreover, the Outcomes Work-
ing Group of the ASCO highlighted the priority of patient-
outcomes, giving a secondary relevance to cancer out-
comes and pharmacoeconomic evaluations. The rele-
vance of survival and quality of life as patient-outcomes
entails two critical issues: a) how to correlate the different
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outcomes in the same clinical approach; and b) how to
evaluate the outcomes in daily clinical practice or clinical
research from a methodological point of view.
In daily clinical practice, response rate is the main crite-
rion to evaluate the outcome of a treatment, as a relation-
ship between response rate and overall survival is
supposed. However, such an assumption can be accepta-
ble for chemo-sensitive diseases (Hodgkin disease, testic-
ular cancer), but it is at least questionable for the most
part of chemo-resistant diseases (Non-Small-Cell Lung
Cancer, gastric or pancreatic cancer). A similar questiona-
ble attitude is represented by the increasing use of symp-
toms control, toxicity or performance status as surrogate
end points of quality of life, whereas the actual assessment
of quality of life remains a neglected end point in clinical
research. Despite the dangerous implications from a
methodological point of view, the use of surrogate end
points of effectiveness is a quite diffuse attitude, that is
rapidly increasing in both clinical research and daily clin-
ical practice. Although the Food and Drugs Administra-
tion (FDA) and EMEA give great relevance to quality of life
as a patient-outcome [1,4], they do not seem to consider
quality of life as an essential outcome when they are
approving new drugs [5,6]. Such an idiosyncrasy of both
clinicians and regulatory agencies for the assessment of
quality of life has favoured the use of several surrogate end
points, potentially misleading and methodologically
questionable.
Surrogate end points of quality of life
In the last years, clinical research paid increasing attention
to quality of life, and many papers investigated quality of
life as an outcome of the treatment and improvement in
the quality of the data [7-9]. However, the assessment of
quality of life is difficult and often inaccurate. Frequent
obstacles in quality of life assessment are represented by
patients compliance, missing data, accuracy of the assess-
ment, usefulness of the tools (validated and not-vali-
dated), complexity of the assessment, and scepticism of
clinicians, researchers and regulators about the value of
health-related quality of life assessment in clinical
research or in clinical practice [10-16]. All these obstacles
have favoured the use (and the abuse) of surrogate end
points of quality of life, the role of which has invaded the
main dimensions of quality of life research, jeopardizing
the correct assessment of health-related quality of life as a
patient-outcome. Surrogate end points are intermediate
end points, that should be related with the main end
point and could represent a preliminary index of the final
outcome. Surrogate end points of survival can be the dis-
ease free interval in the adjuvant setting, or the number of
complete regressions of the disease during chemotherapy
for metastatic cancer [3]. Both parameters, although dif-
ferent from overall survival, may represent a preliminary
index of effectiveness, that can be useful in a preliminary
analysis. Although a preliminary evaluation of effective-
ness with a surrogate end point can be extremely useful if
related with the final outcome, it could be deleterious if
used instead of the evaluation of the final outcome. The
risk of confounding a surrogate end point with a final end
point is a real danger for researchers and regulators, and
the misunderstanding between surrogate and final end
points is not uncommon in oncology.
Surrogate end points of quality of life 
assessment: reasons for the recent 
misunderstanding
In the last years, the "clinical benefit assessment" has
widely been used to evaluate the outcome of palliative
chemotherapy [17]. It was introduced in 1996 by
Rothemberg et al. as a primary end point in a phase II trial
investigating the activity of gemcitabine in metastatic pan-
creatic cancer pre-treated with 5FU [18], and consisted of
the measurement of three debilitating signs or symptoms,
frequent in advanced pancreatic cancer: pain, functional
impairment and weight loss. The trial showed an activity
of this palliative treatment, and was followed by a phase
III trial, that reported an improvement in clinical benefit
and survival for patients with chemotherapy-naive pan-
creatic cancer treated with gemcitabine, in comparison
with patients treated with 5FU [19]. Both these trials,
introducing clinical benefit as an outcome of palliative
chemotherapy, were severely questioned [20-24] for the
following methodological reasons:
- Clinical benefit has never been validated as an outcome
of a palliative treatment in pancreatic cancer.
- Although clinical benefit assessment derived from the
assessment of two primary measures (pain and perform-
ance status) and one secondary measure (weight change),
it was just pain (in particular the reduction in opiate con-
sumption) that significantly differed between responders
and non-responders; this could not be considered enough
to justify an approach with chemotherapy.
- The effectiveness of gemcitabine as palliative treatment
had to be tested against an appropriate palliative treat-
ment (in particular, considering the relevance of pain
assessment in clinical benefit evaluation, against an ade-
quate treatment with opiate), avoiding to use the reduc-
tion of opiate consumption as a partial index of activity.
- The weight of costs and side effects was not adequately
compared with the modest and questionable improve-
ment in the primary end points.
However, these severe criticisms, raised by many authors,
failed to restrict the use of clinical benefit as a surrogateHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/71
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end point of quality of life. On the contrary, it has become
one of the main outcomes not only in the palliative treat-
ment of advanced pancreatic cancer, but also of many
other solid tumours [25,26]. Moreover, on the basis of the
improvement in overall survival and clinical benefit [19],
in 1997 the FDA registered gemcitabine as the treatment
of choice in advanced pancreatic cancer, assuming clinical
benefit as a surrogate end point of quality of life, and pav-
ing the way for a new dangerous era in quality of life
assessment.
Likewise, in 1996 Tannock et al. published the results of a
trial investigating the use of mitoxantrone in advanced
hormone-resistant prostate cancer [27]. Also this trial had
some limits, that were similar to those weakening the tri-
als focused on clinical benefit in advanced pancreatic can-
cer: primary end point was pain control; pain was assessed
using non-validated instruments; the reduction in opiate
consumption was a secondary end point; the control arm
received corticosteroids, that is a questionable treatment if
pain control is the primary end point. Nevertheless,
mitoxantrone was registered by the FDA for the treatment
of advanced hormone-resistant prostate cancer, adopting
pain control (assessed with a non-validated instrument)
as a surrogate end point of quality of life, despite the crit-
icisms and the doubts widely expressed in literature [28-
30]. The group of Tannock successively reviewed the data
of their first experience, analysing either the quality of life
[31], or the pharmacoeconomic dimension, correctly
using a cost-utility model of analysis [32]. Both reports
confirmed the superiority of the experimental arm, but
some perplexities do remain, for either the choice of the
control arm (low doses of prednisone are not universally
accepted as the standard palliative treatment in hormone-
resistant prostate cancer), or the rapid approval by regula-
tors on the basis of the data of the first paper. Also for the
use of mitoxantrone in hormone-resistant prostate cancer
it is evident how dangerous could be an approach to qual-
ity of life based on surrogate end points.
A different, but in one way similar question may be repre-
sented by the recent FDA rapid approval of gefitinib in the
treatment of advanced pre-treated Non-Small-Cell Lung
Cancer. Although in the IDEAL-1 and the IDEAL-2 trials
(the registrative trials) were used validated tools in quality
of life assessment, both of them were planned as phase II
trials, in which the activity, and not the effectiveness of the
treatment were investigated [33-36]. It follows that a cor-
rect tool on one hand, but also an inappropriate design of
the trial on the other hand, were used to register a mole-
cule in the treatment of cancer, underlining once again
how the topic may be still confounding (although the
rules of FDA rapid approval of a drug are obviously
beyond the arguments of this paper). A further dimension
in which the use of surrogate end points of quality of life
could be misleading is palliative care. The quality of the
residual life at the end of life is a very important issue, and
the dimension of quality of life has been widely investi-
gated in the last years [37-39]. Quality of life assessment
at the end of life is a very complex field of quality of life
research, and the use of surrogate end points of quality of
life is just one of the undefined aspects of this field. Pro-
gestins or corticosteroids are the drugs of choice in the pal-
liative treatment of the cancer cachexia syndrome, and
megestrol acetate or medroxyprogesterone acetate likely
represent the gold standard to this aim. However, a recent
systematic review highlighted that no significant improve-
ment in quality of life besides weight gain or appetite
improvement can be inferred from the trials investigating
the role of megestrol acetate or medroxyprogesterone ace-
tate in quality of life [40]. The reasons explaining the lack
of improvement in quality of life assessment can be sum-
marized as follows:
- Insufficient sensitivity of the instruments used for qual-
ity of life assessment (no validated instruments was used
in the selected trials).
- Duration of the treatment and follow up too short to
evaluate the impact of the treatment in overall quality of
life.
- Secondary relevance of cancer cachexia in the status of
terminal or pre-terminal patients.
Moreover, a further fundamental aspect is worthy to be
underlined, as it is likely to concern not only cancer
cachexia, but the most part of palliative care dimensions.
Symptoms control probably represents an index of activity
instead of effectiveness, and it can not be considered by
itself a surrogate end point of quality of life without run-
ning the risk of drawing erroneous conclusions, as it is
probably a relevant, but not fundamental dimension of
quality of life assessment.
Conclusions
Surrogate end points are largely used in clinical research,
and their use can not be considered wrong by a concep-
tual point of view. A surrogate end point is an useful index
to evaluate a final outcome, as it is usually easier to be
evaluated and is evaluable in a shorter time. Conversely,
the use of a surrogate end point instead of a final outcome
is wrong by a methodological point of view and can lead
to draw misleading conclusions. Unfortunately, the use of
surrogate end points in clinical research has gained
ground in the last years, favouring a lot of conclusions
that appear at least questionable when applied to daily
clinical practice. Moreover, the use of surrogate end points
as outcomes of effectiveness has been extended to survival
and even to the assessment of quality of life. The use inHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/71
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clinical research or clinical practice of surrogate end
points such as clinical benefit or pain control is not a
problem by itself. On the contrary, it should be worthy of
renewed attention as concerns cancer-related symptoms
and symptoms control. The actual problem is that the
assessment of clinical benefit or pain is not used with
quality of life assessment, but instead of quality of life
assessment, and such an attitude inevitably reduces the
quality of life dimension to mere symptoms control.
Finally, reviewing the papers reporting data about quality
of life assessment in oncology, some points can be high-
lighted:
- Quality of life assessment represents an independent
outcome in clinical research and an index of effectiveness
of a treatment.
- Surrogate end points of quality of life can represent an
useful instrument in clinical research or daily clinical
practice, on condition that they are used with and within
quality of life assessment.
- The conclusions of trials using surrogate end points of
quality of life instead of quality of life assessment as pri-
mary outcome should be evaluated with caution, and no
definitive conclusion about quality of life should be
drawn from such trials.
- The habit of regulators (FDA or EMEA) of using surro-
gate end points of quality of life to register new drugs
should be handled with great caution, and further con-
firmatory data should be warranted before reaching a
definitive confirmation.
The use of surrogate end points of quality of life can be
useful within a project of quality of life assessment. On
the other hand, the evaluation of quality of life using
solely surrogate end points is incorrect by a methodologi-
cal point of view and can lead to incorrect conclusions,
that are just surrogate responses to surrogate questions.
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